Name in SEC filings: Century Therapeutics, Inc.
Source: ORION, orionbiotechai.com/company/IPSC, data as of Oct 17, 2026
https://www.orionbiotechai.com/company/IPSC
CNTY-101 (CARAMEL IST) · Topline/data readout · in 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Topline/data readoutin 2026
Stage: OtherSEC filing · “Phase 1/2”
Public float: $212,506,473 · as of · SEC filing
CNTY-101 preliminary clinical data from Phase 1/2 CARAMEL IST expected in 2026
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Otherin 2026
Stage: Not stated
Public float: $212,506,473 · as of · SEC filing
CNTY-308, a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy for B-cell-mediated diseases, is anticipated to enter the clinic in 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
NDA/BLA submissionin the fourth quarter of 2026
Stage: —
Public float: $212,506,473 · as of · SEC filing
Investigational New Drug (IND) submission (4Q 2026): Century expects to submit an Investigational New Drug application for CNTY-813 in the fourth quarter of 2026, subject to completion of remaining IND-enabling studies.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-12)
Topline/data readoutin the second half of 2027
Stage: Not stated
Public float: $212,506,473 · as of · SEC filing
Initial clinical data (2H 2027): Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2027-12)
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| CNTY-813Submission | in the fourth quarter of 2026“Investigational New Drug (IND) submission (4Q 2026): Century expects to submit an Investigational New Drug application for CNTY-813 in the fourth quarter of 2026, subject to completion of remaining IND-enabling studies.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| CNTY-813Clinical results | in the second half of 2027“Initial clinical data (2H 2027): Initial safety and early efficacy data from the first-in-human CNTY-813 study are anticipated in the second half of 2027.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| CNTY-308Other | in 2026“CNTY-308, a CD19-targeted CD4+/CD8+ αβ CAR-iT cell therapy for B-cell-mediated diseases, is anticipated to enter the clinic in 2026.” Filed · EX-99.1 | Still within period As of Oct 19, 2026 |
| CNTY-308Other | in 2026“Subject to completion of these IND-enabling studies and receipt of requisite regulatory clearance, we expect CNTY-308 to enter the clinic in 2026.” Filed · 10-Q | Still within period As of Oct 19, 2026 |
| CNTY-101 (CARAMEL IST)Clinical results | in 2026“CNTY-101 preliminary clinical data from Phase 1/2 CARAMEL IST expected in 2026” Filed · EX-99.2 | Still within period As of Oct 19, 2026 |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for IPSC. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.
See IPSC in the calendar · Review labels and methodology